CD163 and ovarian cancer: Lan et al. also assessed the CD163/CD68 expression ratio and reported that platinum‐resistant recurrences were more prevalent in the high‐CD163/CD68 ratio group than in the low‐ratio group (p = 0.020), which suggested that activation of macrophages towards the M2 phenotype might correlate with types of recurrent disease in ovarian cancer (platinum‐resistant recurrence vs. platinum‐sensitive).11